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Abstract 42 
Chronic lymphocytic leukemia (CLL) clones are characterized by loss of a critical region in 43 
13q14.3, [del(13)(q14)] involving the microRNA (miRNA) cluster miR-15a and miR-16-1. We 44 
have investigated the effects of replacement of miR-15a and miR-16-1. CLL cells transfected 45 
with these miRNA mimics exhibited a decrease in cell viability in vitro and impaired capacity 46 
for engraftment and growth in NOD/Shi-scid,γcnull (NSG) mice. No synergistic effects were 47 
observed when the two miRNA mimics were combined. The phenomena were not restricted to 48 
CLL with the del(13)(q14) lesion. Similar effects induced by miRNA mimics were seen in cells 49 
with additional chromosomal abnormalities with the exception of certain CLL clones harboring 50 
TP53 alterations. Administration of miRNA mimics to NSG mice previously engrafted with CLL 51 
clones resulted in substantial tumor regression. CLL cell transfection with miR-15a and miR-16-52 
1 specific inhibitors resulted in increased cell viability in vitro and in an enhanced capacity of the 53 
engrafted cells to grow in NSG mice generating larger splenic nodules. These data demonstrate 54 
that the strong control by miR-15a and miR-16-1 on CLL clonal expansion is exerted also at the 55 




CLL is characterized by the monoclonal expansion of B cells expressing CD19, CD5 and 59 
CD23 and low levels of surface immunoglobulin1. The mechanisms underlying the disease have 60 
only been partially elucidated. In CLL, well-defined chromosomal abnormalities, such as 61 
deletions at (17)(p13.1), (11)(q22.3) or trisomy 12 (+12) are infrequent at early stages and more 62 
common in patients with more advanced disease or at relapse. Therefore, these lesions are 63 
unlikely to contribute to the initial pathogenetic mechanisms, although they may be involved in 64 
both disease progression and resistance to therapy2-8. 65 
The 13q14.3 [del(13)(q14)] deletion represents a remarkable exception, since it is 66 
observed in approximately 50% of cases either in a mono- or biallelic form and is also present in 67 
the early disease stages4, 9, including monoclonal B cell lymphocytosis or MBL10, 11, suggesting a 68 
pathogenetic role. The deletion identified involves primarily the DLEU2 gene which carries the 69 
locus of two microRNAs (miRNAs): miR-15a and miR-16-1 (miR-15 and miR-16, 70 
respectively)12-17. MiRNAs are single stranded, non-coding RNA, which are evolutionary 71 
conserved and capable of regulating the expression of several genes concomitantly18. The 72 
regulation of gene expression occurs mainly through the specific binding of miRNAs to the 3’-73 
un-translated region (3’-UTR) of the messenger RNA of the target gene via a RNA-induced 74 
silencing complex19, although additional mechanisms have been described20. 75 
Biallelic del(13)(q14) results in an incapacity of the cell to express miR-15 and miR-16 76 
(ref. 14, 15, 17, 21, 22) (Supplementary Figure S1) and the deregulation of several target genes, 77 
including those involved in cell cycle progression and apoptosis23-25. This confers an increased 78 
resistance to apoptosis and a propensity to leukemic cell proliferation. Low levels of miR-15 or 79 
miR-16 are observed in patients with monoallelic deletions and in many patients without 80 
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del(13)(q14) (ref. 15, 21, 22, 26-28). Additional support for the role of the miR-15/miR-16 locus 81 
in CLL pathogenesis comes from the New Zealand Black (NZB) mice strain harboring a germ-82 
line point mutation downstream of the miR-16 locus, which prevents normal expression of both 83 
miR-15 and miR-16 and facilitates leukemia onset and possibly autoimmune manifestations29. 84 
An analogous lesion, present in particular families, genetically predisposes humans to CLL and 85 
possibly to other neoplasias30. Finally, the selective deletion of the miR-15/miR-16 locus in mice 86 
predisposes the development of a CLL-like leukemia16, 31. Therefore, impairment of miR-15 and 87 
miR-16 function may be involved in promoting the initial phases of leukemogenesis; however, 88 
little is known regarding the role of these lesions in maintaining the transformed status and the 89 
clonal expansion of full-blown leukemia32. 90 
Here, we investigated the possibility of interfering with both miR-15 and miR-16 91 
expression by CLL cells, both in in vivo and in vitro.   92 
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Materials and Methods 93 
Patients and CLL cell preparations. 94 
Newly diagnosed CLL patients from participating Institutions were enrolled within 12 95 
months from diagnosis in the O-CLL1 protocol (clinicaltrial.gov identifier NCT00917540). All 96 
participants provided written informed consent in accordance with the declaration of Helsinki 97 
and the study was approved by the appropriate institutional review boards. Supplementary Table 98 
S1 summarizes the phenotype and the major cytogenetic features of  CLL cases (n=59) selected 99 
for in vitro (n=48) and in vivo (n=17) experiments reported in this study11, 33, 34.  100 
PBMCs from patients with CLL were isolated by Ficoll-Hypaque (Seromed, Biochrom) 101 
density gradient centrifugation. In selected experiments, CD19-positive CLL cells were enriched 102 
by negative selection with the EasySep-Human B-cell Enrichment Kit without CD43 depletion 103 
(STEMCELL Technologies, Voden Medical Instruments S.p.A).  104 
 105 
Cell transfection 106 
MirVanaTM miRNA mimics or inhibitors (Ambion Inc, Thermo Fisher Scientific, Grand 107 
Island, NY, USA) were delivered to CLL cells with a Neon Transfection System (Invitrogen, 108 
Thermo Fisher Scientific) at the final concentration of 50 nM/2×106 CLL cells. Optimal 109 
transfection and survival of CLL cells was obtained by applying 1 pulse at 2150 pulse voltage 110 
and 20 pulse width, as indicated by the manufacturer for the primary blood-derived suspension 111 
cells protocol. After transfection, cell suspensions were seeded in 24-well plates containing 500 112 
μL of culture medium without antibiotics [RPMI-1640 with L-glutamine and 10% FBS (Gibco, 113 
Thermo Fisher Scientific), Sodium piruvate 0.1% (Euroclone)] at 37°C and incubated at the final 114 
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concentration of 2×106 CLL cells/mL/well in a 5% CO2 atmosphere. The following miRNA 115 
mimics and inhibitors were employed: hsa-miR-15a-5p, hsa-miR-16-5p, and miRNA Negative 116 
Control (CTR)#1, miRNA Inhibitor Negative CTR #1. 117 
 118 
Evaluation of miRNA expression  119 
MiR-15 and miR-16 expression was evaluated with two methods: SmartFlare RNA 120 
Detection Probes (Merck Millipore, France) in n=13 CLL cases and quantitative real time PCR 121 
(q-RT PCR) (n=38 CLL cases), Supplementary materials and methods and Figure S2). 122 
SmartFlare technology is useful to study miRNA expression at the single-cell level. 123 
SmartFlare™ RNA Detection Probes, are constituted by tiny gold nanoparticles conjugated to 124 
oligonucleotides duplexed with reporter strands (oligo+fluorophore). When Smartflare probes 125 
bind to their complementary RNA sequences the fluorophore is released and can be detected by 126 
flow-cytometry (FC). The following Smartflare probes conjugated with the Cyanine 5 (Cy5) 127 
fluorophore were used: SF-430/ miR-15a-5p (miR-15 CY5); SF-178/ miR-16-5p (miR-16 CY5); 128 
SF-102 /Scramble CTR Cy5. The latter reagent does not bind to any RNA sequences within the 129 
cells and is used to measure the level of background fluorescence within CLL cells. Cells were 130 
incubated with Smartflare probes overnight, harvested and analyzed by FACSCanto (BD 131 
Biosciences) and DIVA 6 (BD Biosciences) or FLOWJO V.9.8.3 software (Treestar Inc.). 132 
Counterstaining with propidium iodide (PI; 50 mg/mL, Sigma) in isotonic solution was 133 
employed to evaluate cell viability. 134 
Changes in miR-15/miR-16 expression following transfection with miRNA mimics or 135 
inhibitors were expressed as: 136 
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% fold induction= (%smartflare positive cells transfected with miR-15/miR-16 mimic) - 137 
(%smartflare positive cells transfected with miR-CTR mimic) / (%smartflare positive cells 138 
transfected with miR-15/miR-16 mimic)*100 139 
% fold inhibition= (%smartflare positive cells transfected with miR-CTR inhibitor) - 140 
(%smartflare positive cells transfected with miR-15/miR-16 inhibitor) / (%smartflare positive 141 
cells transfected with miR-CTR inhibitor) *100 142 
 143 
Apoptosis assays 144 
Cultured cells were double stained with Annexin V-FITC conjugate (cat. 556419, BD 145 
Biosciences Pharmingen, San Josè, CA, USA), and PI in isotonic solution, and then analyzed by 146 
FC. Viable cells were defined as double negative cells35. 147 
 148 
Xenogeneic mouse transplantation 149 
Six to eight week old female NOD/Shi-scid,γcnull (NSG) mice (The Jackson Laboratory), 150 
a xenograft model for CLL growth in vivo36, 37 were housed in sterile enclosures under specific 151 
pathogen-free conditions. All procedures involving animals were performed in the respect of the 152 
current National and International regulations and were reviewed and approved by the Licensing 153 
and Animal Welfare Body of the IRCCS-AOU San Martino-IST National Cancer Research 154 
Institute, Genoa, Italy. 155 
Depending on the number of leukemic cells available for animal injection, groups of 2-3 156 
NSG mice were employed for each test and treatment group. The number of animals used for 157 
each treatment is detailed in brackets in Table 1 and Supplementary Tables S3-S5. Full details 158 
are in Supplementary Material and Methods. 159 
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 In miRNA pre-treatment experiments NSG mice (n= 38) were inoculated with CLL cells 160 
(n=6) transfected with miRNA mimic/inhibitors and cultured for 6 h prior to injection. A total of 161 
50x106 CLL cells per mouse were injected together with a proportion of autologous T cells 162 
(approximately 5-10%). 163 
After four weeks, mice were anesthetized by intraperitoneal injection of combination of 164 
xylazine (10 mg/kg) and ketamine (100 mg/kg) and analyzed by Magnetic Resonance Imaging 165 
(MRI) with USPIO contrast reagent38. 166 
On termination of the experiment (maximum 6 weeks from start), animals were sacrificed 167 
in a saturated CO2 chamber and autopsies were performed. Spleens were evaluated by FC and by 168 
immunohistochemical (IHC) analysis. The Animal Welfare Body posed a time limit to the 169 
experimental protocol to prevent unneeded suffering. 170 
Fresh spleen samples were enzymatically digested using the Spleen Dissociation Kit 171 
(Miltenyi Biotec) and mechanically resuspended with gentleMACS™ Dissociator (Miltenyi 172 
Biotec). The single-cell suspensions were stained with anti-human CD45-FITC (555482), CD19-173 
PECy7(557835), CD5-APC(555355), (BD Biosciences) and analyzed by FC. Apoptosis was 174 
evaluated using Annexin-V-FITC, CD19-PE-Cy7, CD5-PE (555353) (BD Biosciences), CD45-175 
APC(130-091-230, Miltenyi Biotec,) cell staining. 176 
Formalin-fixed and paraffin-embedded spleen specimens were analyzed for the presence 177 
of human CLL infiltrates and for the presence of co-injected bystander T-cells by IHC as 178 
detailed above38. The primary antibodies anti-CD20 Mouse monoclonal antibody (760-2531, 179 
clone L26- Ventana Medical System, Roche) and CD3 Rabbit Monoclonal Antibody (790-4341, 180 
clone 2GV6- Ventana Medical System, Roche) were incubated for 30 min at 37°C and signals 181 
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revealed using the polymeric detection system, Ultraview Universal Red Detection Kit (Ventana 182 
Medical System). An appropriate positive tissue control was used for each staining run; the 183 
negative control consisted of performing the entire IHC procedure on adjacent sections in the 184 
absence of the primary antibody; the sections were counter-stained (automatically) with Gill's 185 
modified hematoxylin and then cover-slipped. The sections were evaluated by two observers 186 
with an Olympus light microscope using 4X, 10X, 40X and objectives under a Leica DMD108 187 
optical digital microscope (Leica Microsystems).  188 
To evaluate therapeutic effects of miRNA, CLL (n=11) engraftment in the spleen was 189 
determined by MRI following USPIO contrast reagent injection after 2-3 weeks from cell 190 
injection. At this stage, mice were treated intraperitoneally [every second day with mirVana™ 191 
miRNA mimic, (In Vivo Ready formulation, Ambion Inc)] complexed with Invivofectamine 2.0 192 
(Thermo Fisher Scientific) at a final concentration of 0.7 mg/mL (200 µL/mouse). Overall three 193 
doses were administered. The following miRNA were used: hsa-miR-15a-5p, hsa-miR-16-5p, 194 
miRNA negative control#1. Three days from the last injection, mice (n=74) were analyzed again 195 
by MRI and then sacrificed in a saturated CO2 chamber and autopsies were performed. Spleens 196 
were analyzed by FC and IHC. Apoptosis was evaluated by Annexin-V-FITC, CD19-PE-Cy7, 197 
CD5-PE, CD45-APC, and FC or by Cleaved Caspase-3 (Asp175) (5A1E) Rabbit mAb (9664, 198 
Cell Signaling Technology, Danvers, MA, USA) and IHC on spleen tissue sections. 199 
 200 
Magnetic Resonance Imaging  201 
All in-vivo MRI experiments and MRI analyses, using USPIO nanoparticles, were carried 202 
out and acquired as previously described38. Details are reported in the Supplementary 203 
Information.  204 
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Definition of IHC index  205 
The IHC index is a measure of the spread of leukemia based on the average diameters of 206 
the follicular lesions. We assigned a numerical value of 1 to the follicles with diameters±s.d. of 207 
102(±90) x 42(±7) µm; a value of 3 to follicles with a diameter 195(±80) x 138(±85) µm; a value 208 
of 6 to follicles between 399(±245) x 300(±39), and a value of 12 to follicles between 734(±461) 209 
x 540(±167). The IHC index is given by the sum of the number of follicles multiplied by the 210 
value assigned according to size (Supplementary Figure S3). 211 
 212 
Statistical analysis 213 
The statistical package SPSS for Windows, v13.0, 2004 software (SPSS UK) was used 214 
for all analyses of statistical significance from adequately powered sample sizes for two-tailed 215 
tests. Statistical comparisons between related samples were carried out by nonparametric 216 
Wilcoxon signed rank (paired data) or by Mann-Whitney U (unpaired data) tests. A value of 217 
P<0.05 was considered significant for all statistical calculations. Values are given as 218 
mean±s.e.m. or mean±s.d. as stated in figure legends, which was calculated invariably from n 219 
(the number of patients or animals, biological replicates). All exact P-values are provided in the 220 
figure panels, in figure legends or in Results section.   221 
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Results  222 
Transfection of miR-15 and miR-16 mimics or inhibitors into CLL cells in vitro 223 
Transfection of miRNAs mimics or inhibitors into purified CLL cells was verified by FC 224 
using Smartflare technology and qRT-PCR. 225 
For the experiments with miRNA mimics, 7 CLL cases with biallelic del(13)(q14) 226 
deletions were selected (Supplementary Information and Table S1 for case characteristics). At 227 
24-h after transfection, a significantly larger number of cells were found to express miR-15  228 
(%fold induction=79±5, mean±s.e.m.) and miR-16 (%fold induction=75±5) compared to control 229 
preparations (P=0.015) (Figure 1a and Supplementary Figure S4a). Comparable data were 230 
obtained by qRT-PCR (Supplementary Figure S2a). 231 
For experiments with miRNA inhibitors, we selected 6 CLL cases that did not display 232 
biallelic del(13)(q14) and expressed miR-15 and miR-16 to a variable extent. Transfection with 233 
specific miRNA inhibitors efficiently reduced miRNA expression in all CLL clones compared to 234 
controls (%fold inhibition=54±4, mean±s.e.m., for miR-15; and %fold inhibition=59±4 for miR-235 
16) (P=0.03) (Figure 1c and Supplementary Figure S4b). Again, comparable data were obtained 236 
when miRNA expression was measured by qRT-PCR (Supplementary Figure S2b). 237 
Since miR-15 and miR-16 expression may impact on CLL cell survival in vitro, purified 238 
cells from 12 CLL cases with biallelic del(13)(q14) were transfected with miR-15 or miR-16 239 
miRNA mimics and cultured for up to 72 h. Viable cells were measured at different time 240 
intervals (Supplementary Figure S5a shows the data of a representative experiment). A 241 
significant decrease in cell viability (%fold reduction mean±s.e.m.=53±7 and 48±6 for miR-15 242 
and miR-16 mimics, respectively in 11/12 CLL samples) after 48 h (P=0.001 for miR-15 and 243 
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P=0.0015 for miR-16) was observed. Figure 1b shows the pooled data from the tests performed 244 
while experiments on individual CLL cases are reported in Supplementary Figure S6a. Viability 245 
of cells from the CLL case CG0620, carrying a TP53 mutation, did not change, but the cells from 246 
two other CLL cases (MG0248, PA0254), also displaying TP53 mutations, showed a substantial 247 
drop in cell viability following transfection with either miR-15 or miR-16 (Supplementary Table 248 
S1 and Figure S6a).  249 
Co-transfection of biallelic del(13)(q14) CLL cells with both miR-15 and miR-16 250 
miRNAs never resulted in an additive/synergistic effect (data not shown). Consistent with 251 
previous observations, transfection of miR-15 or miR-16 into del(13)(q14) CLL cells caused 252 
down-regulation of BCL2 or MCL1 (antiapoptotic) and of Cyclin D1 or D2 (cell cycle induction) 253 
proteins encoded by target genes of these miRNAs23, 24. In contrast, Survivin, which is involved 254 
in an alternative apoptotic pathway, was not down-regulated (Supplementary Figure S6b-c). 255 
Inhibition of miR-15 or miR-16 expression with specific miRNA inhibitors resulted in a 256 
substantial increase in CLL cell viability. Supplementary Figure 5b reports the cell viability of a 257 
representative CLL case. A significant increase in cell viability was measured until 48-hours 258 
culture, whereas at 72 hours, a drop in cell viability was observed both in the presence of miR-259 
15/miR-16 inhibitors and in the presence of miR-CTR inhibitor, although there were still 260 
differences in the two conditions. Pooled viability data, measured after a 48-h culture from a 261 
group of 24 CLL cases displaying different cytogenetic features (Supplementary Table S2 and 262 
Supplementary Figure S7), are summarized in Figure 1d (%fold increase=40±3 and 42±4 with 263 
miR-15 or miR-16 inhibitor, respectively; P<0.0001) and show that miRNA inhibition 264 
expression resulted consistently in a better in vitro survival of CLL cells. 265 
 266 
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Effects of in vitro transfection with miRNA-15 or miRNA-16 mimics/inhibitors on the growth 267 
of CLL cells in NSG mice 268 
Purified cells from four CLL cases with biallelic del(13)(q14) were transfected with miR-269 
15, miR-16 or miR-CTR mimics, cultured for 6-h and then injected intravenously (i.v.) into NSG 270 
mice together with autologous T cells (B/T cell ratio 5-10:1). Two/three mice were used for each 271 
treatment group. Disease engraftment was measured after 4 weeks by USPIO-MRI of the 272 
spleen38. Iron uptake is inversely correlated with the presence of CLL follicles-like structures 273 
which prevent iron uptake. Signal-to-Noise ratio change (ΔSNR%) values are higher when low 274 
iron levels enter the splenic tissue. Thus, higher uptake of the USPIO contrast reagent was 275 
observed in the spleens of NSG mice receiving CLL cells transfected with miR-15 or miR-16 276 
mimics which resulted into a lower ΔSNR% value compared to the spleens of mice receiving 277 
miR-CTR-transfected CLL cells (Figure 2a). The ΔSNR% of mice injected with miR-15 278 
(mean±s.d.= −31.1±25.1) or miR-16 (mean±s.d.= −18.2±28.19) mimics pre-treated cells 279 
res.e.m.bled that of NSG mice that had not received leukemic cells (mean±s.d..= −54.3±15), 280 
whereas this value was higher (+30.7±23.4) in the mice receiving miR-CTR pre-treated cells. 281 
ΔSNR% values of mice groups pre-treated with miR-15 (n=7) or with miR-16 (n=6) were 282 
significantly lower compared to those pre-treated with miR-CTR (n=8) (P=0.001 for miR-15; 283 
P=0.01 for miR-16). This MRI pattern was likely related to the lower number of neoplastic foci 284 
within the splenic white pulp, a finding consistent with the observation of a lower number of 285 
follicle-like structures detected by IHC with anti-CD20 mAb in the spleen of mice receiving 286 
miR15/16 treated cells compared to controls. Likewise, the IHC index (as detailed in 287 
Supplementary Figure S3) of mice receiving CLL cells treated with miR-15/16 mimics was 288 
decreased compared to that of mice receiving cells transfected with miR-CTR. The average ±s.d. 289 
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of the IHC index reduction was 68±11 and 67±11 following transfection of miR-15 and miR-16 290 
mimics, respectively (Figure 2c) (P=0.0078 for both miRNAs compared to miR-CTR). FC 291 
showed a significantly lower proportion of CD19+CD5+ cells in the spleens of mice inoculated 292 
with miR-15/16-mimic-transfected CLL cells than in controls (P=0.012) (Figure 2e and 293 
supplementary Figure S8a). B cells recovered from NSG mice consistently shared the same BCR 294 
gene rearrangements as the leukemic clone used for injection, whereas T cells displayed 295 
oligoclonal TCR rearrangments (data not shown). 296 
Cells from two CLL cases (PM0608, PA0145) lacking del(13)(q14) were pre-treated with 297 
miR-15 or miR-16 inhibitors in vitro and subsequently injected into NSG mice together with T 298 
cells according to the same schedule described above. This treatment resulted in a better splenic 299 
engraftment of the CLL cells as documented by the differences in the ΔSNR% (Figure 2b). In the 300 
spleen of mice injected with the cells from PM608 CLL case, these values were of +49±8.4 and 301 
+33±19.3 after pre-treatment of the cells with miR-15 and miR-16 inhibitors, respectively and of 302 
+8±11.1 after cell pretreatment with miR-CTR inhibitors. This was paralleled by an average IHC 303 
index increase (mean±s.d..) of 69±6% and 71±17% respectively, in mice inoculated with miR-15 304 
or miR-16 inhibitor pre-treated cells (P=0.039 for miR-15 and P=0.05 for miR-16 inhibitors 305 
compared to miR-CTR inhibitor, Figure 2d). Consistent with these data was the significant 306 
increase in the percentage of CD45+CD19+CD5+ cells observed by FC in the mice inoculated 307 
with miRNA-inhibitor-treated cells (71±3% and 69±1%, mean±s.d., respectively) (Figure 2f, and 308 
supplementary Figure S8b). All data are detailed in Supplementary Table S3. Again, the BCR 309 
and TCR gene rearrangement analyses confirmed that the engrafted B cells were mostly from the 310 
leukemic clones, whereas T cells were oligoclonal (not shown).  311 
 312 
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Inhibition of CLL cell expansion in NSG mice by treatment with miR-15 and miR-16 mimics. 313 
Next, we investigated whether administration of miRNA mimics could inhibit the 314 
expansion of a previously inoculated CLL clone in NSG mice. In preliminary tests, six NSG 315 
mice were injected with MG0248 CLL cells. After four weeks, a single potentially therapeutic 316 
dose of miR-15 miR-16 or miR-CTR complexed with Invivofectamine was administered 317 
intraperitoneally. Mice were sacrificed 24-h after miRNA administration and CLL cells (CD45+, 318 
CD19+ and CD5+) were purified by FACS sorting from splenic cell suspensions (the resulting 319 
preparations contained >98% CLL cells). qRT-PCR analysis showed an increase of miR-15 (fold 320 
increase=407.80) and of miR-16 (fold increase 34.15) levels above control  mice injected with 321 
miR-CTR (Supplementary Figure S9). 322 
Next, CLL cells from six cases with biallelic del(13)(q14) were inoculated into NSG 323 
mice together with T cells (NSG-CLL) and CLL engraftment was verified in the spleen after 324 
approximately two weeks by MRI38. Mice found to have an above-average splenic ΔSNR%, 325 
compared to NSG mice that had not received leukemic cells (NSG-CTR, n=12, ΔSNR% 326 
−54.3±15, mean±s.d.), were placed on treatment with miR-15 or miR-16 mimics or miR-CTR 327 
(one injection on alternate days for a total of three injections). Three days after the final 328 
treatment, splenic infiltration by leukemic cells was evaluated (Figure 3 and 4). On MRI 329 
(exemplified in Figure 3a and 3b), miR-CTR treated mice displayed a splenic infiltration by 330 
leukemic cells with an 63±14 average increase of ΔSNR% over that of mice not receiving 331 
leukemic cells (p <0.0001). In contrast, mice treated with miR-15 or miR-16 mimics showed a 332 
significant ΔSNR% decrease (P<0.0001 and P=0.0002, respectively) compared to mice before 333 
therapy administration (Figure 3c). The values of the treated mice were similar to those of NSG-334 
CTR mice not receiving CLL cell inocula. The ΔSNR% values of mice treated with miR-CTR 335 
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following CLL cell inoculation were similar to or greater than those at therapy start time point 336 
(P=0.002) (Figure 3c). These results predicted a response to therapy, which was subsequently 337 
confirmed by FC analysis [average percentage CLL cells reduction of 61±8 (P=0.0006) and of 338 
75±12 (P=0.0001) after miR-15 and miR-16 mimics treatment, respectively versus mice treated 339 
with miR-CTR] (Fig 3d) and IHC. A significantly lower IHC index was observed in mice treated 340 
with miR-15 or miR-16 compared to mice treated with miR-CTR [(average IHC index reduction 341 
62±15 (P=0.0007) and 78±22 (P=0.02), respectively] (Figure 3e and Supplementary Table S4).  342 
IHC analysis showed an almost complete disappearance of the typical aggregates of 343 
leukemic (CD20+) cells after treatment with miR-15 or miR-16 mimics (Figure 4a and 344 
Supplementary Figure S3b). However, autologous T cells (CD3+ cells), surrounding what was 345 
presumably the area of the previously existing CLL cell aggregates/nodules, were still present in 346 
a substantial number, possibly indicating that T cells were not affected by treatment (Figure 4b). 347 
Cleaved CASP3 could be observed in the “empty nodules” possibly indicating apoptotic 348 
leukemic cells (Figure 4c and Supplementary Figure S10) as also suggested by the observation of 349 
an increased percentage of Annexin V positive CLL cells (P<0.0001) in the splenic cell 350 
suspension by FC (Figure 4d and Supplementary Table S5).  351 
 352 
Decrease in vitro viability and growth ability of CLL cells with different cytogenetic 353 
features following transfection with miR-15 or miR-16 mimics  354 
We extended our observations to a set of 26 CLL cases lacking biallelic del(13)(q14) 355 
(Figure 5 and Supplementary Table S1). The cells from these cases, which expressed different 356 
levels of miR-15 and miR-16 as evaluated by qRT-PCR (Supplementary Figure S1c,d), were 357 
purified and transfected with miR-15, miR-16 mimics or miR-CTR (Supplementary Figure S2c). 358 
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Cell viability was significantly decreased following transfection in most cases (P<0.001, Figure 359 
5a, b). Decreased cell viability also was observed when the two major CLL groups were 360 
analyzed separately: i.e. those with monoallelic del(13)(q14) [statistically significant differences 361 
in the miR-15-mimic (P=0.01), miR-16-mimic (P=0.005) treated cells compared to controls] and 362 
the group with normal FISH (P=0.004). 363 
In addition, viability of the cells from other cases, including one with del(11)(q22.3), 364 
involving the ATM gene, and others with p53 mutations or del(17)(p13.1) was reduced 365 
following miR-15 and miR-16 mimic transfection . 366 
Finally, NSG mice were engrafted with cells from two cases harboring monoallelic 367 
del(13)(q14) (FP0499, GN0095), one case  with trisomy 12 (RD0468), one with a normal FISH 368 
pattern (VS0624) and one with del(17)(p13.1) and a TP53 mutation on the remaining allele 369 
(RM0626), and were subsequently treated with miR-15 or miR-16 as above. A significant 370 
reduction of splenic disease was observed by FC (P=0.0001 and P=0.006 following miR-15 or 371 
miR-16 mimic treatment, respectively compared to miR-CTR) (Table 1). A decrease in the IHC 372 
index of 72±18% and 74±10% following treatment with miR-15 and miR-16 mimics, 373 
respectively (P=0.001) was observed in four of the CLL cases tested. Case RM0626 represented 374 
a remarkable exception since treatment with the miRNA mimics consistently failed to 375 
significantly block the growth of CLL cells in vivo. Of note is the finding that this case had low 376 
miR-15 and medium to high miR-16 expression. Thus, the findings were unlikely related to the 377 
possibility that the miRNA values were already so high that could not be changed by the 378 
transfection. Rather, a completely dysfunctional TP53 was the possible cause for the findings. 379 
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Discussion  380 
This study demonstrates that in vitro transfection of miR-15 and miR-16 mimics into 381 
CLL cells with del(13)(q14) results in a significant inhibition of their subsequent growth in NSG 382 
mice. Furthermore, administration of miR-15 or miR-16 mimics to NSG mice, in which these 383 
CLL cells were already engrafted and proliferating, caused significant tumor regression. Both 384 
observations are in line with the notion that miR-15 and miR-16 control the cell apoptotic 385 
apparatus and proliferative capacities17, 23, 24. No additive/synergistic effects were noted when 386 
miR-15 and miR-16 mimics were co-transfected, suggesting that the regulatory controls of the 387 
two miRNAs on the expression of other genes largely overlap, a consideration consistent with 388 
the notion that miR-15 and miR-16 interact with the same 3’-UTR region of BCL-2 mRNA24. 389 
Selective inhibition of miR-15 and miR-16 expression in CLL cells resulted in improved 390 
in vitro survival and a more robust expansion in NSG mice16. In contrast, enforced expression of 391 
miR-15 or miR-16 in cells retaining the capacity to express these miRNAs resulted in impaired 392 
in vitro survival or diminished expansion in NSG mice. Both findings provide further support for 393 
the regulatory role of intracellular miR-15/miR-16 concentrations in full-blown CLL 14, 23, 24, 32 394 
(Figure 5). The experimental design utilized here was intended to obtain a specific and selective 395 
inhibition or replacement of miR-15 and miR-16 without further influence of other gene 396 
segments such as Dleu2 or Dleu7 (ref. 39), the absence of which have been shown to synergize 397 
with that of miR-15 and miR-16 in CLL pathogenesis. Thus, the data demonstrate that 398 
low/absent expression of miR-15 and miR-16 plays a crucial pathogenetic role per sè, in line 399 
with the observation that replacement of these miRNAs in NZB mice using suitable viral carriers 400 
blocks the expansion of CLL-like cells both in vivo and in vitro40. 401 
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MiR-15 or miR-16 mimics did not apparently interfere with the function of T cells that 402 
are normally needed to support in vivo CLL cell growth. In the experiments where CLL cell 403 
growth in NSG mice was inhibited by pre-exposure to miR-15/miR-16 mimics in vitro (see 404 
Figure 2), the T cells were added to the purified CLL cells following their in vitro exposure to 405 
these miRNAs. However, in experiments, where transfection was carried out in vitro on 406 
unfractionated cell suspensions, containing both T and CLL cells, before injection into mice, we 407 
observed an unaltered distribution pattern of T cells in the spleen of mice even in the presence a 408 
largely diminished proportion of B cells. Moreover, when mice were treated with miR-15 or 409 
miR-16 mimics in vivo, seemingly unaltered T cell proportions were observed surrounding the  410 
“empty” areas, previously occupied by CLL cells (Figure 4). Thus, inhibition of CLL cell growth 411 
in NSG mice presumably occurred through interference of the transfected mimics with the CLL 412 
cell survival/proliferating apparatus, rather than through an indirect action on the T cells 413 
promoting CLL cell growth. Whether or not progressive CLL cell death, induced by the 414 
transfected miRNA mimics in vivo, may lead to T cell immune-priming capable of causing 415 
further CLL cell elimination is presently unknown. 416 
A final issue concerns the potential use of miR-15 and miR-16 for therapy. MiRNA 417 
mimics are effective on CLL cells growing in vivo and on CLL cells with additional 418 
chromosomal alterations; however, some results from both in vivo and in vitro experiments 419 
showed that the presence of TP53 gene mutations/deletions may render administration of the 420 
miR-15 and miR-16 mimics ineffective. This is expected, given the close interactions between 421 
miR-15 and miR-16, TP53 and the cluster of miR-34 genes in the regulation of cell 422 
survival/apoptosis41, 42. Nevertheless, not all cases with TP53 defects failed to respond to miRNA 423 
mimics treatment suggesting heterogeneity of functional TP53 alterations. These observations 424 
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are being extended to additional cohorts of patients including more advanced stage/relapsed 425 
patients that more frequently harbor additional TP53 alterations43-46. 426 
We provide proof of principle data supporting the potential use of miRNA mimics to 427 
block CLL clonal expansion. Additional miRNAs, other than miR-15 or miR-16, may become 428 
suitable therapeutic targets, since a number of studies have demonstrated anomalous expression 429 
of various miRNAs in CLL cells compared to normal cells11, 22, 30. Moreover, when certain 430 
miRNA are overexpressed, they can be targeted by miRNA inhibitors47. Several anomalies in 431 
miRNA expression have prognostic/predictive value for disease course and outcome, indicating a 432 
potential mechanistic role in the disease pathogenesis/progression22-24, 30, 48-52. Thus, the miRNA 433 
approach, especially if multiple miRNA mimics and inhibitors can be targeted, either alone or in 434 
combination with other drugs, may represent an additional therapeutical strategy. In connection 435 
with this, it should be noted that therapy with miR inhibition/replacement is being employed in a 436 
variety of experimental tumors. Moreover, there are many available studies on human tumors, 437 
some of which have reached the clinical stage I, with potentially promising results53. Thus, miR 438 
therapy may represent a “real” tool in the future armamentarium of drugs usable in CLL, a 439 
disease that so far has escaped attempts towards a radical cure.   440 
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Figure legends 709 
Figure 1. Transfection with miRNA mimics and inhibitors and variations in CLL cell 710 
viability in vitro. (a) Expression of miR-15 and miR-16 following transfection with miR-15 (% 711 
of positive CLL cells mean±s.e.m.=55.7±5.2) or miR-16 (49.1±7.6) or miR-CTR mimics 712 
(10.9±2.2 for miR-15; 10.8±1.9 for miR-16) determined by smartflare technology. Summary of 713 
tests on 7 CLL cases with biallelic del(13)(q14) (MG0248, DT0300, MA0088, LD0062, 714 
GM0041, RD0296, GD0051).(b) Summary of  viability determinations obtained on cells from 12 715 
different biallelic del(13)(q14) CLL cases after a 48-h culture following transfection of the 716 
indicated miRNA-mimics (data for individual cases are reported in Supplementary Figure S6a). 717 
The asterisks indicate data from a CLL case (CG0620) harboring the TP53 mutation 718 
(Supplementary Table S1). (c) Expression of miR-15 and miR-16 following transfection with 719 
miR-15 (23.17±3) or miR-16 (16.5±2.8) or miR-CTR inhibitors (50.17±6.4 for miR-15; 720 
38.17±4.2 for miR-16). Summary of tests on 6 CLL cases (CP0036, CR0203, PA0145, PM0608, 721 
CG0623, MA0342). (d) Summary of the viability results obtained on cells from 24 CLL cases 722 
transfected with miRNA inhibitors.  In (a) and (c) purified CLL cells were transfected with the 723 
indicated miRNA mimics or inhibitors and cultured overnight in the presence of miR-15-CY5, 724 
miR-16-CY5 or scramble CY5 Smartflare probes. Counter staining with propidium iodide (PI) 725 
was employed to evaluate cell viability (see also Supplementary Figure S4). In (b) and (d) viable 726 
cells (%) are measured as Annexin-V/PI-double negative cells (Supplementary Figure S5). The 727 
P-values were obtained by Wilcoxon test in all panels. 728 
 729 
Figure 2. CLL cell engraftment in NSG mice following in vitro transfection with miRNA 730 
mimics or inhibitors. Representative tests on mice engrafted with CLL cells pre-treated in vitro 731 
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with miRNA mimics (CLL CD0310), miRNA inhibitors (CLL PM0608), or miRNA-CTR. (a-b) 732 
The figure shows the MRI images  24h  after USPIO administration. The position of the spleen is 733 
indicated by the dotted red outline. ΔSNR% values also are indicated.  The spleens with superior 734 
iron uptake and consequent lower ΔSNR% values, appear darker and less nodular. Conversely, 735 
spleens with lower iron uptake and higher ΔSNR% values are not so dark and show a nodular 736 
structure possibly related to the presence of follicles. Additional explanations are given in text. 737 
(c-d) α-CD20 Ab staining (red) of paraffin tissue embedded spleen samples following injection 738 
of CLL cells pre-treated with the indicated miRNA (d). The CD20+ follicle-like structures are 739 
highlighted by red squares in (c) (magnification 40x). The 400x magnification of a representative 740 
follicle for each panel is shown. IHC index is indicated in each panel. (e-f) Flow-cytometry 741 
analysis of cells from of the same spleens used for the IHC analyses shown in (c) and (d). CLL 742 
cells (CD5+/CD19+) and T cells (CD5+/CD19-) were identified on gated huCD45-positive cells 743 
(Supplementary Figure S8). (e) Pooled flow-cytometry data obtained from 4 CLL cases with 744 
biallelic del(13)(q14) pre-treated with miRNA mimics in vitro before injection into mice (n=8 745 
mice for each treatment group). The cells, harvested from mice at the end of tests, were stained 746 
and counted. Statistical comparisons were carried out using Wilcoxon-matched pair test. A P-747 
value=0.0078 is indicated by **. (f) Pooled flow-cytometry data on cells from 2 CLL cases with 748 
normal FISH pre-treated in vitro with miRNA inhibitors prior to injection into mice (n=5 mice 749 
for miR-CTR, n=4 for miR-15 and n=5 for miR-16 inhibitors). * and ** indicate P=0.016 and 750 
P=0.007 P-values respectively (Mann-Whitney U test). In (e-f) values are expressed as 751 
mean±s.d. and detailed in Supplementary Table S3. 752 
 753 
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Figure 3. Effects of in vivo treatment with miRNA mimics on CLL cells engrafted in NSG 754 
mice. (a-b) MRI analysis of the spleen before and after the indicated treatment (representative 755 
experiment with cells from MP0456 CLL case).  (MRI) images obtained 24 h after Spleens 756 
which are characterized by high USPIO uptake appear darker and less granular, a finding which 757 
correlates with a low presence of leukemic follicles. See text and legend to Fig. 2 for additional 758 
details. (c) Summary of MRI results observed on cells from 6 CLL cases biallelic for 759 
del(13)(q14) treated with the indicated miRNA mimics. After 2 weeks from CLL cells injection 760 
(NSG-CLL, grey dots), mice displayed ΔSNR% values significantly higher compared to those 761 
not receiving CLL cells (NSG-CTR, green dots). NSG-CLL mice treated with miR-15 (red dots) 762 
or miR-16 (blue dots) mimics had significantly different MRI patterns from the same mice 763 
before therapy or after treatment with miR-CTR (black dots). (d) Summary of the flow-764 
cytometry analysis of freshly isolated cells from the same spleens analyzed in (c). Percentages of 765 
CD19+CD5+ CLLs cells or CD19-CD5+ T cells detected by gating CD45+ cells are expressed 766 
as mean±s.d.. (e) Summary of the IHC analysis of splenic tissue stained by α-CD20 mAb. In (c, 767 
d, e) each dot represents an individual mouse. Values also are expressed as mean±s.d.. Statistical 768 
comparisons were carried out using Mann-Whitney U test. All data are detailed in 769 
Supplementary Table S4. 770 
 771 
Figure 4. Effects of treatment with miR-15 or miR-16 mimics on the expansion of CLL 772 
clones in NSG mice. (a-b) IHC analysis of the spleen of a mouse a representative CLL case 773 
(MP0456).The typical CD20+ aggregates (a) surrounded by CD3+ T cells (b), that are evident in 774 
the spleens of the mice treated with miR-CTR, virtually disappear following treatment with miR-775 
15 or miR-16 mimics. 40x magnification view of splenic sagittal sections. The inset indicates the 776 
same areas at a higher magnification (400x). (c) Numerous cells were stained by α-Cleaved 777 
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Caspase 3 mAb in the spleen of mice treated with miR-15. These were virtually absent in mice 778 
treated with miR-CTR (magnification 200x and 400x in the inset). (d) Summary of flow-779 
cytometry results observed in mice injected with the cells from 6 CLL cases biallelic for 780 
del(13)(q14.3). Annexin-V positive cells were determined at the end of the experiment. Each dot 781 
represents an individual mouse. Values are expressed as mean±s.d.. Statistical comparisons were 782 
carried out using Mann-Whitney U test (****P<0.0001). All data are detailed in Supplementary 783 
Table S5. 784 
 785 
Figure 5. Effects of treatment with miRNA mimics on the growth of cells from CLL with 786 
non-biallelic del(13)(q14. (a) Determination of viable cells (measured as Annexin V/PI- 787 
negative cells) in 26 CLL cases at 48-h culture following transfection of the indicated miRNA 788 
mimics. CLL cases were grouped according to their karyotype. The asterisks indicate CLL cases 789 
carrying TP53 alterations (Supplementary Table S1). (b) Summary of the results of the 26 CLLs 790 
cases (left panel) and subdivided in cases with monoallelic del(13)(q14) (n=12) (central panel) 791 








Table 1. Inhibition of non biallelic del(13q14) CLL cell growth in NSG mice by miR-15 or 




(n of mice) 
CD45+CD19+CD5+ 
CLL cells (FC) 
% (mean±s.d.) 
CD45+CD19-CD5+ 





miR-CTR mimic (3) 9±1.7 90±0.9 137±36.8 
miR-15 mimic (3) 4±0.7 87±2.1 72±10.8 
miR-16 mimic (2) 2±0.3 86±8 26±7.4 
      
GN0095 
miR-CTR mimic (2) 13±0.5 82±2.8 107±12.7 
miR-15 mimic (3) 8±1.8 86±2.9 12±10 
miR-16 mimic (3) 7±0.7 82±8.5 23±13.7 
          
RD0468 
miR-CTR mimic (4) 13±5.4 51±10.7 56±5.5 
miR-15 mimic (3) 4±1.4 60±2.8 12±5.8 
miR-16 mimic (3) 5±1.5 51±8.4 14±9.8 
      
VS0624 
miR-CTR mimic (3) 18±1.9 81±2.7 248±45.1 
miR-15 mimic (3) 8±3.6 87±7.6 68±7.5 
miR-16 mimic (3) 14±1.9 79±6.9 101±35.1 
        
RM0626 
miR-CTR mimic (3) 46±12.7 51±15.4 65±12.9 
miR-15 mimic (2) 58±2.5 36±1.4 53±3.5 
miR-16 mimic (2) 63±1.8 28±5.4 53±8.5 
FC= flow-cytometry; IHC index= immunohistochemical index.  
